Dysfunctional uterine bleeding future or investigational therapies: Difference between revisions
m (Bot: Removing from Primary care) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Dysfunctional uterine bleeding}} | {{Dysfunctional uterine bleeding}} | ||
{{CMG}}{{AE}}[[User:AroojNaz|Arooj Naz]] | |||
==Overview== | |||
Abnormal uterine bleeding has been found to affect a multitude of women, ranging from menarche to menopause. It can often result in conditions that affect an individual's daily routine and personal life, such as anemia and infertility. Because of such complications, it is important to continue researching and studying the causes of abnormal bleeding and providing further knowledge.<ref name="pmid28716637">{{cite journal| author=Levy-Zauberman Y, Pourcelot AG, Capmas P, Fernandez H| title=Update on the management of abnormal uterine bleeding. | journal=J Gynecol Obstet Hum Reprod | year= 2017 | volume= 46 | issue= 8 | pages= 613-622 | pmid=28716637 | doi=10.1016/j.jogoh.2017.07.005 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28716637 }} </ref> Due to the prevalence and high cost associated with surgical treatment of underlying causes, treatment must be tailored to the individual woman. Biomarkers continue to be studied and may provide crucial information.<ref name="pmid30388215">{{cite journal| author=Chodankar R, Critchley HOD| title=Biomarkers in abnormal uterine bleeding†. | journal=Biol Reprod | year= 2019 | volume= 101 | issue= 6 | pages= 1155-1166 | pmid=30388215 | doi=10.1093/biolre/ioy231 | pmc=6931000 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30388215 }} </ref> | |||
==Future or Investigational Therapies== | |||
===Biomarkers===<ref name="pmid30388215">{{cite journal| author=Chodankar R, Critchley HOD| title=Biomarkers in abnormal uterine bleeding†. | journal=Biol Reprod | year= 2019 | volume= 101 | issue= 6 | pages= 1155-1166 | pmid=30388215 | doi=10.1093/biolre/ioy231 | pmc=6931000 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30388215 }} </ref> | |||
A biomarker is an indicator that may be measured and used as an indicator for treatment response. Biomarers have been studied for underlying conditions leading to abnormal bleeding. | |||
==References== | ==References== | ||
Revision as of 06:48, 18 March 2022
|
Dysfunctional uterine bleeding Microchapters |
|
Differentiating Dysfunctional uterine bleeding from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Dysfunctional uterine bleeding future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Dysfunctional uterine bleeding future or investigational therapies |
|
FDA on Dysfunctional uterine bleeding future or investigational therapies |
|
CDC on Dysfunctional uterine bleeding future or investigational therapies |
|
Dysfunctional uterine bleeding future or investigational therapies in the news |
|
Blogs on Dysfunctional uterine bleeding future or investigational therapies |
|
Directions to Hospitals Treating Dysfunctional uterine bleeding |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Arooj Naz
Overview
Abnormal uterine bleeding has been found to affect a multitude of women, ranging from menarche to menopause. It can often result in conditions that affect an individual's daily routine and personal life, such as anemia and infertility. Because of such complications, it is important to continue researching and studying the causes of abnormal bleeding and providing further knowledge.[1] Due to the prevalence and high cost associated with surgical treatment of underlying causes, treatment must be tailored to the individual woman. Biomarkers continue to be studied and may provide crucial information.[2]
Future or Investigational Therapies
===Biomarkers===[2] A biomarker is an indicator that may be measured and used as an indicator for treatment response. Biomarers have been studied for underlying conditions leading to abnormal bleeding.
References
- ↑ Levy-Zauberman Y, Pourcelot AG, Capmas P, Fernandez H (2017). "Update on the management of abnormal uterine bleeding". J Gynecol Obstet Hum Reprod. 46 (8): 613–622. doi:10.1016/j.jogoh.2017.07.005. PMID 28716637.
- ↑ 2.0 2.1 Chodankar R, Critchley HOD (2019). "Biomarkers in abnormal uterine bleeding†". Biol Reprod. 101 (6): 1155–1166. doi:10.1093/biolre/ioy231. PMC 6931000 Check
|pmc=value (help). PMID 30388215.